Bradykinin B2 receptor-mediated transport into intact cells: Anti-receptor antibody-based cargoes

European Journal of Pharmacology

Volumn 668, Issue 1-2, 2011, Pages 107-114

  Bawolak, Marie Thérèse ^a   Lodge, Robert ^b   Morissette, Guillaume ^a   Marceau, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Arrestin; B2 receptor; Bradykinin; Receptor endocytosis

Indexed keywords

AUTOANTIGEN; BETA ARRESTIN; BRADYKININ; BRADYKININ B2 RECEPTOR; MONOCLONAL ANTIBODY; MYC ANTIBODY; MYC PROTEIN; QUANTUM DOT; UNCLASSIFIED DRUG; EPITOPE; RETINA S ANTIGEN;

ARTICLE; CALCIUM SIGNALING; CELL TRANSPORT; CELL VACUOLE; CONJUGATION; CONTROLLED STUDY; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; CELL STRAIN HEK293; DRUG EFFECT; DRUG POTENTIATION; EXTRACELLULAR SPACE; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN TRANSPORT;

ANTIBODIES, MONOCLONAL; ARRESTINS; BRADYKININ; EPITOPES; EXTRACELLULAR SPACE; GENETIC VECTORS; HEK293 CELLS; HUMANS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, BRADYKININ B2;

EID: 80052058115     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.06.041     Document Type: Article

References (19)

1. S. Abd Alla, U. Quitterer, S. Grigoriev, A. Maidhof, M. Haasemann, K. Jarnagin, and W. Müller-Esterl Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies J. Biol. Chem. 271 1996 1748 1755 (Pubitemid 26028663)
2. 2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates J. Pharmacol. Exp. Ther. 297 2001 19 26 (Pubitemid 32242559)
3. M.T. Bawolak, L. Gera, G. Morissette, J.M. Stewart, and F. Marceau B-9972 (D-Arg-[Hyp3, Igl5, Oic7, Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3, Igl5, D-Igl7, Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation J. Pharmacol. Exp. Ther. 323 2007 534 546 (Pubitemid 350005113)
4. 2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging Peptides 29 2008 1626 1630
5. 2 receptors Br. J. Pharmacol. 158 2009 1375 1386
6. V. Bernier, M. Lagacé, M. Lonergan, M.F. Arthus, D.G. Bichet, and M. Bouvier Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059 Mol. Endocrinol. 18 2004 2074 2084 (Pubitemid 39006510)
7. P. Diagaradjane, J.M. Orenstein-Cardona, N.E. Colón-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D.L. Schwartz, J.G. Gelovani, and S. Krishnan Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe Clin. Cancer Res. 14 2008 731 741 (Pubitemid 351231154)
8. 2 receptor-mediated agonist endocytosis and trafficking and of angiotensin converting enzyme J. Pharmacol. Exp. Ther. 337 2011 33 41
9. B.L. Grosshans, D. Ortiz, and P. Novick Rabs and their effectors: achieving specificity in membrane traffic Proc. Natl Acad. Sci. USA 103 2006 11821 11827 (Pubitemid 44215770)
10. A. Hurtado-Lorenzo, M. Skinner, J. El Annan, M. Futai, G.H. Sun-Wada, S. Bourgoin, J. Casanova, A. Wildeman, S. Bechoua, D.A. Ausiello, D. Brown, and V. Marshansky V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway Nat. Cell Biol. 8 2006 124 136
11. Y. Kabeya, N. Mizushima, T. Ueno, A. Yamamoto, T. Kirisako, T. Noda, E. Kominami, Y. Ohsumi, and T. Yoshimori LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing EMBO J. 19 2000 5720 5728
12. T.G. Kutateladze, K.D. Ogburn, W.T. Watson, T. de Beer, S.D. Emr, C.G. Burd, and M. Overduin Phosphatidylinositol 3-phosphate recognition by the FYVE domain Mol. Cell 3 1999 805 811 (Pubitemid 29323059)
13. L.M.F. Leeb-Lundberg, F. Marceau, W. Müller-Esterl, D.J. Pettibone, and B.L. Zuraw International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences Pharmacol. Rev. 57 2005 27 77 (Pubitemid 40283969)
14. P. Lin, J.W. Chen, L.W. Chang, J.P. Wu, L. Redding, H. Chang, T.K. Yeh, C.S. Yang, M.H. Tsai, H.J. Wang, Y.C. Kuo, and R.S.H. Yang Computational and ultrastructural toxicology of a nanoparticle, quantum dot 705, in mice Environ. Sci. Technol. 42 2008 6264 6270
15. F. Marceau, M.T. Bawolak, J. Bouthillier, and G. Morissette Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: a model for the distribution of lipophilic cationic drugs to autophagic vacuoles Drug Metab. Dispos. 37 2009 2271 2274
16. 2 bradykinin receptor. Modeling of nonpeptidic ligand action and comparison to the rhodopsin structure J. Biol. Chem. 276 2001 41100 41111
17. C.M. Munoz, and L.M.F. Leeb-Lundberg Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradation pathways J. Biol. Chem. 267 1992 303 309
18. S.S. Rizk, A. Luchniak, S. Uysal, C.M. Brawley, R.S. Rock, and A.A. Kossiakoff An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells Proc. Natl Acad. Sci. USA 106 2009 11011 11015
19. C. Tekle, B. van Deurs, K. Sandvig, and T.G. Iversen Cellular trafficking of quantum dot-ligand bioconjugates and their induction of changes in normal routing of unconjugated ligands Nano Lett. 8 2008 1858 1865